Livzon Pharmaceutical Group details extensive A-share buyback program

Livzon Pharmaceutical Group announced significant A-share buyback activities, with the latest disclosure detailing transactions up to November 7, 2025. On this date, the company repurchased 160,100 A-shares through other stock exchanges, with prices ranging from RMB 36.94 to RMB 37.74 per share, totaling an expenditure of RMB 5,996,356. All repurchased shares are intended for cancellation, as indicated by a "zero" balance for shares held as treasury stock.

This recent activity is part of a broader ongoing buyback program. Throughout late 2024 and 2025, Livzon Pharmaceutical Group has consistently repurchased A-shares. For instance, in December 2024, daily buybacks ranged from 144,000 to 145,700 shares. In January 2025, daily repurchases saw a peak of 561,400 A-shares on January 14, and continued with figures such as 274,900 shares on January 20. February 2025 saw repurchases like 558,400 shares on February 12 and 13.

The buyback program continued through April and August 2025, with repurchases on April 8 for 293,900 shares and on August 13 for 101,500 shares. September 2025 also recorded significant activity, including 131,000 shares repurchased on September 23. The company's total issued H-shares (excluding treasury shares) remained at 299,807,117 on November 7, 2025, while issued A-shares (excluding treasury shares) stood at 604,293,313, reflecting the impact of these ongoing buybacks.